Publications in collaboration with researchers from Hospital Universitari de Bellvitge (10)

2024

  1. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

    npj Breast Cancer, Vol. 10, Núm. 1

2023

  1. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

    Annals of Oncology, Vol. 34, Núm. 8, pp. 670-680

2022

  1. Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial

    European Journal of Cancer, Vol. 174, pp. 232-242

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. The role of CDK4/6 inhibitors in early breast cancer

    Breast, Vol. 58, pp. 160-169

2020

  1. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464

  2. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)

    Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 469-479

2019

  1. SEOM clinical guidelines in early stage breast cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 18-30

2018

  1. Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii90

2015

  1. SEOM clinical guidelines in early-stage breast cancer 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 939-945